文献速递胸部肿瘤放疗姑息放疗与转移瘤放疗物理与技术

靶向或免疫治疗进展期NSCLC的转移灶立体定向放疗:TOaSTT数据库疗效与安全性

Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database.
PubMed 文献 · Radiat Oncol · 2021-01-06

本研究基于多中心回顾性TOaSTT数据库,评估IV期NSCLC患者在靶向或免疫治疗(TT/IT)期间同步(≤30天)接受转移灶立体定向放疗(SRT)的安全性与疗效。108例患者共192个病灶接受SRT,同步TT/IT以EGFR/ALK抑制剂为主(60%)。寡进展(OPD)患者2年OS为51%,多进展(PPD)为25%;严重急性与晚期毒性分别为5.5%和1.9%。

要点

  • TT/IT期间同步转移灶SRT严重毒性低,急性5.5%、晚期1.9%。
  • OPD患者2年OS 51%,PPD患者25%,无治疗相关死亡。
  • 单器官转移者PFS更优且TTS延长6个月。

核心结论

  • NSCLC患者在TT/IT期间同步进行转移灶SRT安全性良好,严重毒性风险低。
  • 进展后继续TT/IT联合SRT似乎有前景,但需前瞻性评估。

研究设计与样本

  • 多中心回顾性队列,纳入IV期NSCLC接受TT/IT并同步(≤30天)转移灶SRT的患者。
  • 共108例患者、192个病灶,治疗时间2009年7月至2018年5月。
  • 56%为寡进展(OPD),44%为多进展(PPD)。
  • 生存分析采用Kaplan-Meier法和log rank检验,毒性按CTCAE v4.03评分。

主要发现

  • 同步TT/IT包括EGFR/ALK抑制剂60%、免疫检查点抑制剂31%、VEGF抗体8%、PARP抑制剂1%。
  • OPD患者2年OS为51%,PPD患者为25%。
  • 1年后,58%的OPD患者和39%的PPD患者仍维持原TT/IT。
  • SRT后第二次进展为寡转移(≤5个病灶)者占59%。
  • 严重急性毒性和晚期毒性分别见于5.5%和1.9%的患者,无治疗相关死亡。

关键数值与推荐

  • 多因素分析中,OS受临床转移状态影响(p=0.002,HR 2.03,95%CI 1.30-3.17)。
  • PFS在接受一线系统治疗的患者中更优(p=0.033,HR 1.7,95%CI 1.05-2.77)。
  • PFS在仅一个器官受转移影响的患者中更优(p=0.023,HR 2.04,95%CI 1.10-3.79)。
  • TTS在单器官转移患者中延长6个月(p=0.031,HR 2.53,95%CI 1.09-5.89)。

临床怎么用

  • 对TT/IT治疗中的NSCLC患者,可考虑对进展病灶行同步转移灶SRT,严重毒性风险低。
  • 寡进展患者可能从同步SRT中更多获益,单器官转移者PFS和TTS更优。

局限性

  • 回顾性研究设计,证据等级有限。
  • 需前瞻性临床试验进一步确定最佳治疗顺序和获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastasis directed treatment (MDT) is increasingly performed with the attempt to improve outcome in non-small cell lung cancer (NSCLC) patients receiving targeted- or immunotherapy (TT/IT). This study aimed to assess the safety and efficacy of metastasis directed stereotactic radiotherapy (SRT) concurrent to TT/IT in NSCLC patients. METHODS: A retrospective multicenter cohort of stage IV NSCLC patients treated with TT/IT and concurrent (≤ 30 days) MDT was established. 56% and 44% of patients were treated for oligoprogressive disease (OPD) or polyprogressive disease (PPD) under TT/IT, polyprogressive respectively. Survival was analyzed using Kaplan-Meier and log rank testing. Toxicity was scored using CTCAE v4.03 criteria. Predictive factors for overall survival (OS), progression free survival (PFS) and time to therapy switch (TTS) were analyzed with uni- and multivariate analysis. RESULTS: MDT of 192 lesions in 108 patients was performed between 07/2009 and 05/2018. Concurrent TT/IT consisted of EGFR/ALK-inhibitors (60%), immune checkpoint inhibitors (31%), VEGF-antibodies (8%) and PARP-inhibitors (1%). 2y-OS was 51% for OPD and 25% for PPD. After 1 year, 58% of OPD and 39% of PPD patients remained on the same TT/IT. Second progression after MDT was oligometastatic (≤ 5 lesions) in 59% of patients. Severe acute and late toxicity was observed in 5.5% and 1.9% of patients. In multivariate analysis, OS was influenced by the clinical metastatic status (p = 0.002, HR 2.03, 95% CI 1.30-3.17). PFS was better in patients receiving their first line of systemic treatment (p = 0.033, HR 1.7, 95% CI 1.05-2.77) and with only one metastases-affected organ (p = 0.023, HR 2.04, 95% CI 1.10-3.79). TTS was 6 months longer in patients with one metastases-affected organ (p = 0.031, HR 2.53, 95% CI 1.09-5.89). Death was never therapy-related. CONCLUSIONS: Metastases-directed SRT in NSCLC patients can be safely performed concurrent to TT/IT with a low risk of severe toxicity. To find the ideal sequence of the available multidisciplinary treatment options for NSCLC and determine what patients will benefit most, a further evaluated in a broader context within prospective clinical trials is needed continuation of TT/IT beyond progression combined with MDT for progressive lesions appears promising but requires prospective evaluation. TRIAL REGISTRATION: retrospectively registered.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Kroeze SGC, Schaule J, Fritz C, et al. Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or immunotherapy: efficacy and safety reporting from the 'TOaSTT' database. Radiat Oncol. 2021. PMID: 33407611. doi:10.1186/s13014-020-01730-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。